+

WO2001049299A3 - Prevention of ironotecan induced diarrhea with activated carbon - Google Patents

Prevention of ironotecan induced diarrhea with activated carbon Download PDF

Info

Publication number
WO2001049299A3
WO2001049299A3 PCT/CA2000/001544 CA0001544W WO0149299A3 WO 2001049299 A3 WO2001049299 A3 WO 2001049299A3 CA 0001544 W CA0001544 W CA 0001544W WO 0149299 A3 WO0149299 A3 WO 0149299A3
Authority
WO
WIPO (PCT)
Prior art keywords
ironotecan
prevention
activated carbon
induced diarrhea
diarrhea
Prior art date
Application number
PCT/CA2000/001544
Other languages
French (fr)
Other versions
WO2001049299A2 (en
Inventor
Malcolm J Moore
Michael Michael
Original Assignee
Malcolm J Moore
Michael Michael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Malcolm J Moore, Michael Michael filed Critical Malcolm J Moore
Priority to AU23356/01A priority Critical patent/AU2335601A/en
Publication of WO2001049299A2 publication Critical patent/WO2001049299A2/en
Publication of WO2001049299A3 publication Critical patent/WO2001049299A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Irinotecan is an anti-cancer drug whose use sometimes causes diarrhea in patients. The invention provides a method of preventing or mitigating the diarrhea by administration of carbon to patients in need thereof.
PCT/CA2000/001544 2000-01-06 2000-12-21 Prevention of ironotecan induced diarrhea with activated carbon WO2001049299A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23356/01A AU2335601A (en) 2000-01-06 2000-12-21 Treatment or prevention of diarrhea

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,295,429 2000-01-06
CA002295429A CA2295429A1 (en) 2000-01-06 2000-01-06 Treatment or prevention of diarrhea

Publications (2)

Publication Number Publication Date
WO2001049299A2 WO2001049299A2 (en) 2001-07-12
WO2001049299A3 true WO2001049299A3 (en) 2002-02-21

Family

ID=4165060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001544 WO2001049299A2 (en) 2000-01-06 2000-12-21 Prevention of ironotecan induced diarrhea with activated carbon

Country Status (5)

Country Link
AR (1) AR026791A1 (en)
AU (1) AU2335601A (en)
CA (1) CA2295429A1 (en)
PE (1) PE20010990A1 (en)
WO (1) WO2001049299A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454643A1 (en) * 2001-07-23 2003-02-20 Epidauros Biotechnologie Ag Methods for the treatment of cancer with irinotecan based on cyp3a5
WO2004103371A1 (en) * 2003-05-21 2004-12-02 Pharmacia & Upjohn Company Llc Use of cftr inhibitors for the treatment of chemotherapy-induced diarrhea

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065493A1 (en) * 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
WO2000007605A1 (en) * 1998-08-05 2000-02-17 Aventis Pharma S.A. Use of camptothecin derivatives, with reduced gastrointestinal toxicity
WO2001052828A2 (en) * 2000-01-18 2001-07-26 University Of Massachusetts Glutamine prevention of delayed-onset irinotecan-induced diarrhea

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065493A1 (en) * 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
WO2000007605A1 (en) * 1998-08-05 2000-02-17 Aventis Pharma S.A. Use of camptothecin derivatives, with reduced gastrointestinal toxicity
WO2001052828A2 (en) * 2000-01-18 2001-07-26 University Of Massachusetts Glutamine prevention of delayed-onset irinotecan-induced diarrhea

Also Published As

Publication number Publication date
CA2295429A1 (en) 2001-07-06
PE20010990A1 (en) 2001-09-22
AR026791A1 (en) 2003-02-26
AU2335601A (en) 2001-07-16
WO2001049299A2 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
WO2005048942A3 (en) Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
WO2004075832A3 (en) Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
AU2001285054A1 (en) Subcutaneous infusion cannula
AU2001257563A1 (en) Apparatus and method of intravenous fluid infusion
MXPA03008045A (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors.
AU2002233986A1 (en) Rigid soluble materials for use with needle-less infusion sets, sensor sets and injection devices and methods of making the same
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
ZA200300434B (en) Medicinal herbal compounds for the prevention and treatment of diabetes.
WO2001062290A3 (en) Methods and compositions for improving sleep
AU2002366274A1 (en) Needleless hypodermic injection device
WO2002008217A3 (en) COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
IL136512A0 (en) Intravenous infusion administration set
AU2002236647A1 (en) Method and device for administering medication and/or placebo
AU2002213698A1 (en) Needleless syringe for the subcutaneous delivery of therapeutic agents
WO2003057143A3 (en) A method and device for reducing therapeutic dosage
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2002070524A3 (en) N-but-3-enyl norbuprenorphine and its use as analgesic
WO2005105094A3 (en) Cancer treatment method
AU2003241047A1 (en) Injection needlestick injury prevention device
AP2002002446A0 (en) Method for administering a phosphodiesterase 4 inhibitor.
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
WO2001049299A3 (en) Prevention of ironotecan induced diarrhea with activated carbon
WO2008002641A3 (en) Protein phosphatase inhibitors
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
WO2001070233A3 (en) Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载